RPG Life Sciences (RPGLIFE) Q2 25/26 earnings summary

Executive summary

• Achieved 17.2% year-over-year growth in domestic formulations for Q2 FY26, outpacing the Indian pharma market's 7.7% growth; H1 growth at 13.5% versus market's 7.4%.

• H1 FY26 revenue grew 3.8% year-over-year to ₹350.6 crore, with domestic formulations leading at 71% of sales.

• Naprosyn, the largest brand, grew 16% YOY in H1 and is on track to become the first 100 crore brand.

• Immunosuppressant and mAbs portfolios saw double-digit growth, with mAbs up 21% in H1.

• Unaudited results for Q2 FY26 show continued profitability and growth, with the resignation of the CFO effective October 23, 2025.

Financial highlights

• Q2 FY26 revenue rose 7.6% sequentially to ₹181.7 crore, with year-over-year growth of 5.5%.

• EBITDA for Q2 FY26 was ₹43.6 crore, margin at 24.0%; H1 FY26 EBITDA at ₹84.3 crore, down 5.6% year-over-year.

• Net profit for Q2 FY26 was ₹3,685 lakhs, with EPS at ₹22.28.

• H1 FY26 PAT (excluding exceptionals) at INR 15.6 crore; H1 PAT margin at 15.6%.

• Exceptional income of ₹1,122 lakhs in Q2 FY26, mainly from insurance proceeds related to the fire incident.

Outlook and guidance

• API business expected to recover in H2 as plant resumes full operations.

• Strategic focus on portfolio development, mega-brand building, API growth, digitalization, and M&A.

• Ongoing capex and plant modernization to support growth and regulatory compliance.

• Confident of recovering net loss from the fire incident through insurance in subsequent quarters.